evaluate the pharmaceuticals company zepbound on glp-1 efficacy / effectiveness New Zepbound-Like Drug Leads to 16% More Weight Loss GLP-1 trends 2025: real-world data,

In another study, people taking Contrave lost an average of 510% of their body weight over 12 months when the medicine was combined with a healthy diet and regular exercise

But the clinical evidence is overwhelming

Semaglutide should only be used under the supervision of a licensed medical professional.

Non-alcoholic fatty liver disease (NAFLD) affects approximately one in three UK adults and typically causes no symptoms in early stages

Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial